Compass Therapeutics, Inc. (CMPX)

US — Healthcare Sector
Peers: IDYA  ANAB  MGTX  KROS  FIXX  GLUE  NAMS  IVA  CGEM  PEPG  TYRA  VIGL  PRTC  AVTE  ELVN  MLTX  GPCR  REPL  NVCT  LYRA  KRON  GOSS 

Automate Your Wheel Strategy on CMPX

With Tiblio's Option Bot, you can configure your own wheel strategy including CMPX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CMPX
  • Rev/Share 0.0268
  • Book/Share 1.0059
  • PB 2.0877
  • Debt/Equity 0.0497
  • CurrentRatio 31.8385
  • ROIC -0.4

 

  • MktCap 290394300.0
  • FreeCF/Share -0.3496
  • PFCF -6.0373
  • PE -6.0499
  • Debt/Assets 0.0461
  • DivYield 0
  • ROE -0.3237

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 3
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade CMPX Leerink Partners Market Perform Outperform -- $6 April 2, 2025
Initiation CMPX Guggenheim -- Buy -- $12 Feb. 24, 2025
Initiation CMPX Piper Sandler -- Overweight -- $12 Feb. 19, 2025
Initiation CMPX D. Boral Capital -- Buy -- $32 Dec. 23, 2024
Upgrade CMPX Ladenburg Thalmann Neutral Buy -- $5 Sept. 16, 2024

News

Compass Therapeutics to Participate in Upcoming May Investor Events
CMPX
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May. Details are as follows: The Citizens Life Sciences Conference Location: New York, NY Date: Thursday, May 8, 2025 Time: 1:30 PM ET Webcast Link: https://wsw.com/webcast/jmp65/cmpx/1692592 H.C.

Read More
image for news Compass Therapeutics to Participate in Upcoming May Investor Events
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting
CMPX
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors. Combining CTX-471 with tovecimig (CTX-009) markedly increased anti-tumor efficacy in these models.

Read More
image for news Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
CMPX
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first patient has been dosed in an Investigator Sponsored Trial (IST) to evaluate tovecimig (CTX-009, a DLL4 x VEGF-A bispecific antibody) for the first time in the front-line setting for patients with biliary tract cancer (BTC). The IST is being conducted at The University of Texas MD Anderson Cancer Center.

Read More
image for news Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
CMPX
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the first quarter 2025. Supported initiation of an Investigator Sponsored Study (IST) evaluating tovecimig in patients with BTC in the first-line setting, with patient dosing expected in the first quarter 2025.

Read More
image for news Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

About Compass Therapeutics, Inc. (CMPX)

  • IPO Date 2021-04-05
  • Website https://www.compasstherapeutics.com
  • Industry Biotechnology
  • CEO Dr. Thomas J. Schuetz M.D., Ph.D.
  • Employees 35

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.